OneSource Specialty Pharma's (NSE:ONESOURCE, BOM:544292) Unit 2 facility in Bengaluru, India has been granted good manufacturing practices (GMP) certification from Brazilian health regulatory agency ANVISA, according to a Thursday filing to the Indian bourses.
The GMP certification follows a successful regulatory inspection held in November 2024.
The Unit 2 site is dedicated to manufacturing biologics drug substances and finished products, including drug device combinations (DDC) and other injectable products.
With this approval, the company can now supply pharmaceutical products, especially DDCs to the Brazilian market when the customers getting their product approvals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.